Hongwen Gao

Hongwen Gao


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Human Pathology
Verified
Journal Article
Closed access
LCLanqing Cao
Lanqing Cao
PSPing-Li Sun
Ping-Li Sun
MYMin Yao
Min Yao
MJMeng Jia
Meng Jia
HGHongwen Gao
Hongwen Gao

13 June 2016 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
JYJing-Bo Yang
Jing-Bo Yang
MKMuhammad Khan
Muhammad Khan
YHYang-Yang He
Yang-Yang He
MYMin Yao
Min Yao
YLYong-Ming Li
Yong-Ming Li
ARAzhar Rasul
Azhar Rasul

3 October 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LYLina Yang
Lina Yang
LLLi Liu
Li Liu
HGHongwen Gao
Hongwen Gao
JPJaya Pratap Pinnamaneni
Jaya Pratap Pinnamaneni
DSDeepthi Sanagasetti
Deepthi Sanagasetti
JYJianchang Yang
Jianchang Yang
The stem cell factor spalt-like transcription factor 4 (SALL4) plays important roles in normal hematopoiesis and also in leukemogenesis. We previously reported that SALL4 exerts its effect by recruiting important epigenetic factors such as DNA methyltransferases DNMT1 and lysine-specific demethylase 1 (LSD1/KDM1A). Both of these proteins are critically involved in mixed lineage leukemia (MLL)-rearranged (MLL-r) leukemia, which has a very poor clinical prognosis. Recently, SALL4 has been further linked to the functions of MLL and its target gene homeobox A9 (HOXA9). However, it remains unclear whether SALL4 is indeed a key player in MLL-r leukemia pathogenesis. Using a mouse bone marrow retroviral transduction/ transplantation approach combined with tamoxifen-inducible, CreERT2-mediated Sall4 gene deletion, we studied SALL4 functions in leukemic transformation that was induced by MLL-AF9—one of the most common MLL-r oncoproteins found in patients. In addition, the underlying transcriptional and epigenetic mechanisms were explored using chromatin immunoprecipitation (ChIP) sequencing (ChIP-Seq), mRNA microarray, qRT-PCR, histone modification, co-immunoprecipitation (co-IP), cell cycle, and apoptosis assays. The effects of SALL4 loss on normal hematopoiesis in mice were also investigated. In vitro and in vivo studies revealed that SALL4 expression is critically required for MLL-AF9-induced leukemic transformation and disease progression in mice. Loss of SALL4 in MLL-AF9-transformed cells induced apoptosis and cell cycle arrest at G1. ChIP-Seq assay identified that Sall4 binds to key MLL-AF9 target genes and important MLL-r or non-MLL-r leukemia-related genes. ChIP-PCR assays indicated that SALL4 affects the levels of the histone modification markers H3K79me2/3 and H3K4me3 at MLL-AF9 target gene promoters by physically interacting with DOT1-like histone H3K79 methyltransferase (DOT1l) and LSD1/KDM1A, and thereby regulates transcript expression. Surprisingly, normal Sall4 f/f /CreERT2 mice treated with tamoxifen or vav-Cre-mediated (hematopoietic-specific) Sall4 −/− mice were healthy and displayed no significant hematopoietic defects. Our findings indicate that SALL4 critically contributes to MLL-AF9-induced leukemia, unraveling the underlying transcriptional and epigenetic mechanisms in this disease and suggesting that selectively targeting the SALL4 pathway may be a promising approach for managing human MLL-r leukemia.

1 January 2018 in International Journal of Medical Sciences
Verified
Journal Article
Open access
YHYangyang He
Yangyang He
MKMuhammad Khan
Muhammad Khan
JYJingbo Yang
Jingbo Yang
MYMin Yao
Min Yao
SYShili Yu
Shili Yu
HGHongwen Gao
Hongwen Gao
Cardiac glycosides are natural compounds used for the treatment of congestive heart failure and cardiac arrhythmias. Recently, they have been reported to exhibit anticancer activity. Proscillaridin A (PSN-A), a cardiac glycoside constituent of Urginea maritima has been shown to exhibit anticancer activity. However, the cellular targets and anticancer mechanism of PSN-A in various cancers including prostate cancer remain largely unexplored. In the present study, we have shown that PSN-A inhibits proliferation and induces apoptosis in prostate cancer cells in a dose-dependent manner. Further mechanistic study have shown that anticancer activity of PSN-A in prostate cancer cells is associated with ROS generation, Bcl-2 family proteins modulation, mitochondrial membrane potential disruption and ultimately activation of caspase-3 and cleavage of PARP. Moreover, we found that PSN-A inhibits JAK2/STAT3 signaling and augments doxorubicin toxicity in prostate cancer cells. Of note, LNCaP cells were found to be more sensitive to PSN-A treatment as compared to DU145 cells. Taken together, the data provided first evidence of the anticancer activity and possible molecular mechanism of PSN-A in prostate cancer. Further study is needed to develop PSN-A into a potential lead compound for the treatment of prostate cancer.

11 June 2015 in APMIS
Verified
Journal Article
Closed access
PDF file
XMXianglin Mei
Xianglin Mei
YXYang Xia
Yang Xia
HSHironobu Sasano
Hironobu Sasano
HGHongwen Gao
Hongwen Gao

20 May 2016 in APMIS
Verified
Journal Article
Closed access
PDF file
LZLian Zhang
Lian Zhang
MYMin Yao
Min Yao
MHMasanori Hisaoka
Masanori Hisaoka
HSHironobu Sasano
Hironobu Sasano
HGHongwen Gao
Hongwen Gao